Clinical Trial Update: First-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults [Phase 1]

View source ↗

Summary

This document describes an early-phase, first-in-human safety and immunogenicity study of the vaccine candidates SCB-1022 and SCB-1033 in healthy older adults, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• SCB-1022
• SCB-1033

Snippet

Sponsor: Clover Biopharmaceuticals AUS Pty | Conditions: Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination | Phase 1 | Status: RECRUITING